AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21734063 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine administered with HPV-16/18 AS04-adjuvanted vaccine (HepB+HPV group)
Number of subjects: 148
Study 21734063 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine administered alone (HepB group)
Number of subjects: 148
Study 19712717 — intervention group
Group type: EXPERIMENTAL
Intervention: flavored solution consumed prior to 30 min running exercise
Number of subjects: 58
Study 19712717 — intervention group
Group type: EXPERIMENTAL
Intervention: flavored solution merely tasted prior to 30 min running exercise
Number of subjects: 58
Study 19712717 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise-related gastrointestinal distress
Number of subjects: 58
Study 16672064 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine 4% gel (1.1 g applied for 30 minutes)
Number of subjects: 54
Study 16672064 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1.1 g applied for 30 minutes)
Number of subjects: 54
Study 16672064 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine 4% gel
Number of subjects: 54
Study 16672064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 15231423 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphagia intervention 1
Number of subjects: 0
Study 15231423 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphagia intervention 2
Number of subjects: 0
Study 15231423 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 11230783 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (0.1 mg/kg/min) during insulin infusion
Number of subjects: 20
Study 11230783 — intervention group
Group type: COMPARATOR
Intervention: Insulin infusion (40 mU/m2/min for young, 34 mU/m2/min for old)
Number of subjects: 20
Study 9259113 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide (Sdx, 50 mg bid orally for 6 months)
Number of subjects: 86
Study 9259113 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline (Ptx, 400 mg tid orally for six months)
Number of subjects: 86
Study 7653754 — intervention group
Group type: EXPERIMENTAL
Intervention: Open hernia repair under local infiltration block (group A)
Number of subjects: 59
Study 7653754 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic hernia repair under general anaesthesia (group B)
Number of subjects: 59
Study 2670605 — intervention group
Group type: EXPERIMENTAL
Intervention: VMCP/VBAP (n = 42)
Number of subjects: 86
Study 2670605 — intervention group
Group type: COMPARATOR
Intervention: MP (n = 44)
Number of subjects: 86
Study 576833 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproterol (Bronchspasmin) administered at doses of 3 x 20 mg/day (some patients received 6 x 10 mg/day) for four weeks
Number of subjects: 0
Study 576833 — intervention group
Group type: COMPARATOR
Intervention: Orciprenaline administered at doses of 3 x 20 mg/day (some patients received 6 x 10 mg/day) for four weeks
Number of subjects: 0
Study 31954186 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Number of subjects: 20
Study 31189165 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHO
Number of subjects: 124
Study 31189165 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG
Number of subjects: 124
Study 31189165 — intervention group
Group type: EXPERIMENTAL
Intervention: QuickOpt
Number of subjects: 124
Study 31189165 — intervention group
Group type: COMPARATOR
Intervention: Nominal AV/VV
Number of subjects: 124
Study 28707086 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid and carboxymethylcellulose (HA‐CMC)
Number of subjects: 77
Study 28707086 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid and hydroxyethyl starch (HA‐HES)
Number of subjects: 77
Study 24936126 — intervention group
Group type: COMPARATOR
Intervention: ETV 0.5 mg daily
Number of subjects: 59
Study 24936126 — intervention group
Group type: EXPERIMENTAL
Intervention: ETV 1 mg daily
Number of subjects: 59
Study 21703801 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-length catheters (SC)
Number of subjects: 100
Study 21703801 — intervention group
Group type: COMPARATOR
Intervention: Long catheters (LC)
Number of subjects: 100
Study 20171839 — intervention group
Group type: EXPERIMENTAL
Intervention: PEDro total score
Number of subjects: 9456
Study 20171839 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual scale items contributing to PEDro total score
Number of subjects: 9456
Study 18404563 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentha piperita oil
Number of subjects: 0
Study 18404563 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 0
Study 18404563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuminum cyminum oil
Number of subjects: 0
Study 15842263 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-immediate protocol (Im)
Number of subjects: 46
Study 15842263 — intervention group
Group type: COMPARATOR
Intervention: Delayed protocol (De)
Number of subjects: 46
Study 12749439 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary LH‐timed endometrial and blood sampling
Number of subjects: 68
Study 10505810 — intervention group
Group type: EXPERIMENTAL
Intervention: Polishing of the exposed root surface at slow speed with a rubber cup and prophylaxis paste for 60 seconds
Number of subjects: 10
Study 10505810 — intervention group
Group type: COMPARATOR
Intervention: Root planing of the exposed root surface with a sharp curet
Number of subjects: 10
Study 7603605 — intervention group
Group type: EXPERIMENTAL
Intervention: sCT suppositories at the dose of 100 UI/day
Number of subjects: 30
Study 7603605 — intervention group
Group type: EXPERIMENTAL
Intervention: sCT suppositories at the dose of 200 UI every other day
Number of subjects: 30
Study 2234829 — intervention group
Group type: EXPERIMENTAL
Intervention: Near retinoscopy (NEAR) method
Number of subjects: 0
Study 2234829 — intervention group
Group type: COMPARATOR
Intervention: Nott retinoscopy with DOG target
Number of subjects: 0
Study 355027 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily)
Number of subjects: 68
Study 355027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 30893166 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sublative bipolar fractional radiofrequency (FRF) and 0.1% topical tretinoin
Number of subjects: 18
Study 30893166 — intervention group
Group type: COMPARATOR
Intervention: Sublative bipolar fractional radiofrequency (FRF)
Number of subjects: 18
Study 30893166 — intervention group
Group type: COMPARATOR
Intervention: 0.1% topical tretinoin
Number of subjects: 18
Study 28416587 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled long-acting beta2-agonist (vilanterol 25 µg)
Number of subjects: 16485
Study 28416587 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (fluticasone furoate 100 µg)
Number of subjects: 16485
Study 28416587 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (fluticasone furoate 100 µg and vilanterol 25 µg)
Number of subjects: 16485
Study 28416587 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 16485
Study 26088809 — intervention group
Group type: EXPERIMENTAL
Intervention: Private pour-flush latrines shared by multiple households
Number of subjects: 760
Study 26088809 — intervention group
Group type: COMPARATOR
Intervention: Existing shared private latrines in poor sanitary conditions
Number of subjects: 760
Study 23315402 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral feedback with written information
Number of subjects: 72
Study 23315402 — intervention group
Group type: COMPARATOR
Intervention: Oral feedback only
Number of subjects: 72
Study 21977857 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine plus rehabilitation
Number of subjects: 134
Study 21977857 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine plus acupuncture
Number of subjects: 134
Study 21977857 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine and acupuncture plus rehabilitation
Number of subjects: 134
Study 21977857 — intervention group
Group type: COMPARATOR
Intervention: Western medicine piracetam
Number of subjects: 134
Study 19828234 — intervention group
Group type: COMPARATOR
Intervention: Poorly vascularized tumors (group A)
Number of subjects: 42
Study 19828234 — intervention group
Group type: EXPERIMENTAL
Intervention: Well vascularized tumors (group B)
Number of subjects: 42
Study 19828234 — intervention group
Group type: COMPARATOR
Intervention: Presence of poorly vascularized tumor at CEUS
Number of subjects: 42
Study 19828234 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS enhancement pattern
Number of subjects: 42
Study 17074146 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (aspirin, clopidogrel, cilostazol)
Number of subjects: 120
Study 17074146 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (aspirin, clopidogrel)
Number of subjects: 120
Study 15639697 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 80 mg/d alone (n = 69)
Number of subjects: 147
Study 15639697 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 80 mg/d plus cholestyramine 16 g/d (n = 75)
Number of subjects: 147
Study 15639697 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 80 mg/d plus cholestyramine 16 g/d
Number of subjects: 147
Study 15639697 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 80 mg/d alone
Number of subjects: 147
Study 11508705 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg) in rats
Number of subjects: 0
Study 11508705 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg) in athletes
Number of subjects: 0
Study 10332375 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer materials (Fuji II LC, Photac-Fil, and Vitremer)
Number of subjects: 80
Study 10332375 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacid-modified resin composite (Dyract)
Number of subjects: 80
Study 10332375 — intervention group
Group type: COMPARATOR
Intervention: All materials (including control)
Number of subjects: 80
Study 8500310 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies including worksite, public site, mass mail, telephone, media, and referral strategies.
Number of subjects: 73000
Study 3325092 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal dosing with levodopa
Number of subjects: 11
Study 3325092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30508987 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflatable balloon catheter
Number of subjects: 60
Study 30508987 — intervention group
Group type: COMPARATOR
Intervention: Balloon-less catheter
Number of subjects: 60
Study 27349359 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback device (CPRmeter)
Number of subjects: 60
Study 27349359 — intervention group
Group type: COMPARATOR
Intervention: No feedback device
Number of subjects: 60
Study 24419482 — intervention group
Group type: EXPERIMENTAL
Intervention: intervention diet
Number of subjects: 56
Study 24419482 — intervention group
Group type: COMPARATOR
Intervention: control diet
Number of subjects: 56
Study 22230825 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAMcare program
Number of subjects: 214
Study 22230825 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 214
Study 20919606 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 7.2%‐tretinoin 0.025% gel (CTG) combination product
Number of subjects: 26
Study 20919606 — intervention group
Group type: COMPARATOR
Intervention: Separate daily applications of clindamycin phosphate gel 1% and tretinoin cream 0.025% (C gel + T cream)
Number of subjects: 26
Study 18263673 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular track
Number of subjects: 27
Study 18263673 — intervention group
Group type: COMPARATOR
Intervention: Straight track
Number of subjects: 27
Study 15735198 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients with amputation
Number of subjects: 3711
Study 15735198 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients with poor visual acuity
Number of subjects: 3711
Study 15735198 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients with macrovascular disease
Number of subjects: 3711
Study 15735198 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients with worsening levels of nephropathy
Number of subjects: 3711
Study 15735198 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients with worsening levels of neuropathy
Number of subjects: 3711
Study 15735198 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients with worsening levels of retinopathy
Number of subjects: 3711
Study 15735198 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients with worsening visual acuity
Number of subjects: 3711
Study 12538365 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 4 mg kg(‐1) h(‐1) (Group A)
Number of subjects: 45
Study 12538365 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 5 mg kg(‐1) h(‐1) (Group B)
Number of subjects: 45
Study 12538365 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 6 mg kg(‐1) h(‐1) (Group C)
Number of subjects: 45
Study 11053824 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorylcholine (PC) coating of the extracorporeal circuit
Number of subjects: 20
Study 11053824 — intervention group
Group type: COMPARATOR
Intervention: Control group (no coating)
Number of subjects: 20
Study 8805887 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver sulphadiazine and chlorhexidine impregnated CVC (SSD/CVC)
Number of subjects: 54
Study 8805887 — intervention group
Group type: COMPARATOR
Intervention: Standard triple lumen CVC (STD/CVC)
Number of subjects: 54
Study 8805887 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin Analysing System (FAS) brush
Number of subjects: 54
Study 1640003 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 66
Study 1640003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 1640003 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 66
Study 1640003 — intervention group
Group type: COMPARATOR
Intervention: Non-FH primary hypercholesterolemia
Number of subjects: 66
Study 6234015 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (0.05 mg/kg/day)
Number of subjects: 27
Study 6234015 — intervention group
Group type: COMPARATOR
Intervention: Cyproterone acetate (5 mg daily)
Number of subjects: 27
Study 6234015 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin + Cyproterone acetate
Number of subjects: 27
Study 6234015 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 27
Study 31084761 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE-MRI parameters (Ktrans, Kep, Ve, Vp, area under the curve, peak, time-to-peak)
Number of subjects: 38
Study 31084761 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE-MRI parameters (minimum Vp)
Number of subjects: 38
Study 31084761 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE-MRI parameters (Ve, Vp, time-to-peak)
Number of subjects: 38
Study 30059420 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior turbinate reduction during SRP operation
Number of subjects: 32
Study 30059420 — intervention group
Group type: COMPARATOR
Intervention: No inferior turbinate reduction during SRP operation
Number of subjects: 32
Study 26748629 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancrelipase replacement therapy
Number of subjects: 57
Study 26748629 — intervention group
Group type: COMPARATOR
Intervention: Conventional pancreatic enzyme supplementation
Number of subjects: 57
Study 26748629 — intervention group
Group type: COMPARATOR
Intervention: Crossover to pancrelipase replacement therapy upon NAFLD diagnosis in control group
Number of subjects: 57
Study 24561732 — intervention group
Group type: EXPERIMENTAL
Intervention: CS Reducer implantation
Number of subjects: 23
Study 22413808 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine therapy
Number of subjects: 1036
Study 22413808 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose > 10 mmol/l at week 6/8 or week 12
Number of subjects: 1036
Study 22413808 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose < 8.9 mmol/l at week 6/8 or week 12
Number of subjects: 1036
Study 19237681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (upper‐limb ischemia 6 times a day for 1 month)
Number of subjects: 30
Study 16769171 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine for 12 weeks
Number of subjects: 1913
Study 16769171 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 1913
Study 15126526 — intervention group
Group type: EXPERIMENTAL
Intervention: L-T(4) replacement therapy
Number of subjects: 45
Study 15126526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 11486120 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk restraint (using a harness)
Number of subjects: 11
Study 11486120 — intervention group
Group type: COMPARATOR
Intervention: Unrestrained reaching
Number of subjects: 11
Study 9926059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive community care
Number of subjects: 138
Study 9926059 — intervention group
Group type: COMPARATOR
Intervention: Standard community care
Number of subjects: 138
Study 7803416 — intervention group
Group type: EXPERIMENTAL
Intervention: Omentum group
Number of subjects: 36
Study 7803416 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal mammary artery group
Number of subjects: 36
Study 7803416 — intervention group
Group type: COMPARATOR
Intervention: No wrap group
Number of subjects: 36
Study 3388180 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with parenteral morphine (GA group)
Number of subjects: 100
Study 3388180 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia combined with epidural bupivacaine and epidural morphine (EP group)
Number of subjects: 100
Study 30142849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultralow-dose CT (ULDCT)
Number of subjects: 57
Study 30142849 — intervention group
Group type: COMPARATOR
Intervention: Standard low-dose CT (LDCT)
Number of subjects: 57
Study 27085251 — intervention group
Group type: EXPERIMENTAL
Intervention: Codrituzumab 1600mg biweekly
Number of subjects: 185
Study 27085251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 25355667 — intervention group
Group type: EXPERIMENTAL
Intervention: Aversive events occurring in the past
Number of subjects: 0
Study 25355667 — intervention group
Group type: EXPERIMENTAL
Intervention: Aversive events occurring in the future
Number of subjects: 0
Study 23887766 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 12 mg triamcinolone acetonide at the end of surgery
Number of subjects: 54
Study 23887766 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroid injection)
Number of subjects: 54
Study 20002501 — intervention group
Group type: EXPERIMENTAL
Intervention: AmB+Fluc400
Number of subjects: 64
Study 20002501 — intervention group
Group type: EXPERIMENTAL
Intervention: AmB+Fluc800
Number of subjects: 64
Study 20002501 — intervention group
Group type: COMPARATOR
Intervention: AmB alone
Number of subjects: 64
Study 20002501 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (800 mg/day)
Number of subjects: 64
Study 18568181 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/benazapril (CCB/ACEI)
Number of subjects: 0
Study 18568181 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide/benazapril
Number of subjects: 0
Study 15966653 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer instrument without local anesthesia (LA)
Number of subjects: 20
Study 15966653 — intervention group
Group type: COMPARATOR
Intervention: Carbide bur with local anesthesia (LA)
Number of subjects: 20
Study 12829925 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose calcitriol
Number of subjects: 0
Study 12829925 — intervention group
Group type: COMPARATOR
Intervention: Control (standard immunosuppressive therapy)
Number of subjects: 0
Study 10202235 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with antibiotics
Number of subjects: 80
Study 10202235 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 80
Study 9199120 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined method (surgery and radiotherapy) with moderate postoperative dose of irradiation (5500-6000 cGy)
Number of subjects: 213
Study 9199120 — intervention group
Group type: COMPARATOR
Intervention: Control group treated by radical neck dissection (RND), modified neck dissection (MND), or regional modified neck dissection (RMND) with moderate postoperative dose of irradiation (5000-5500 cGy)
Number of subjects: 213
Study 9199120 — intervention group
Group type: COMPARATOR
Intervention: Exclusively irradiated group
Number of subjects: 213
Study 1946180 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary syringe (4 IU/ml)
Number of subjects: 14
Study 1946180 — intervention group
Group type: COMPARATOR
Intervention: Injection pen (12 IU/ml)
Number of subjects: 14
Study 7180061 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive programme
Number of subjects: 2023
Study 7180061 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2023
Study 30871233 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet (n = 38)
Number of subjects: 75
Study 30871233 — intervention group
Group type: COMPARATOR
Intervention: Control diet (n = 37)
Number of subjects: 75
Study 27709277 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI‐MRE with Buscopan
Number of subjects: 30
Study 27709277 — intervention group
Group type: COMPARATOR
Intervention: DWI‐MRE without Buscopan
Number of subjects: 30
Study 26140494 — intervention group
Group type: EXPERIMENTAL
Intervention: Double procedures (using both STA branches)
Number of subjects: 71
Study 26140494 — intervention group
Group type: COMPARATOR
Intervention: Single procedures (using only 1 STA branch)
Number of subjects: 71
Study 26140494 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diabetes mellitus (DM)
Number of subjects: 71
Study 26140494 — intervention group
Group type: COMPARATOR
Intervention: Patients without diabetes mellitus (DM)
Number of subjects: 71
Study 23756315 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.23% fluoride foam
Number of subjects: 100